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We examined the role of tumor necrosis factor (TNF-α) and its related signaling intermediates leading to apoptosis/proliferation
in the peripheral blood mononuclear cells (PBMCs) of RA patients. The constitutive expression of mRNA for TNF-α receptors
(TNFR-I and TNFR-II) and the adapter molecules, such as the TNF receptor-associated death domain protein (TRADD), Fas-
associated death domain protein (FADD), receptor interacting protein (RIP), and TNF receptor-associated factor 2 (TRAF-2)
were analyzed by reverse transcriptase-PCR (RT-PCR) in PBMCs from control and RA cases. PBMCs of RA patients showed
a signiﬁcant increase in TNF-α and TNFR-I expression as compared with that from control subjects along with signiﬁcantly
increasedconstitutiveexpressionofTRADD,RIP,andTRAF-2mRNA.TherewasadecreaseinexpressionofFADDinRApatients,
but the diﬀerence was not signiﬁcant as compared to controls. These data suggested enhanced signaling by the TNFR-I-TRADD-
RIP-TRAF-2 pathway and suppressed signaling by the TNFR-I-TRADD-FADD pathway in PBMCs of RA patients. However, the
regulatory mechanisms for TNF-α induced signaling may not be explained only by these pathways.
Copyright © 2006 Sunil Kumar Raghav et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
INTRODUCTION
Abnormal proliferation and/or persistence of synoviocytes
and inﬂammatory cells has long been described in inﬂam-
matory arthritis conditions, but only recently substantial at-
tention has been drawn to the relevance of abnormal apop-
totic processes in disease pathogenesis and treatment [1].
Rheumatoid arthritis (RA) is a chronic inﬂammatory disor-
d e rwi t ha u t o i m m u n ef e a t u r e st h a ta ﬀects approximately 1%
of the world’s population. It is characterized by inﬂamma-
tion of synovial tissue and the formation of rheumatoid pan-
nus, which is capable of eroding adjacent cartilage and bone
causing subsequent joint destruction. Although the precise
etiology of the disease is unknown, genetic and environmen-
tal factors seem to be involved in its pathogenesis [2]. Previ-
ous studies have indicated that the relative risk of develop-
ing the disease in siblings of aﬀected individuals (λs) is 2–17
times higher as compared to the general population, suggest-
ing the importance of genetic factors in rheumatoid arthritis
[3]. Recently we reported an association of mannose binding
lectin gene polymorphisms with the occurrence and disease
progression[4].TheassociationofTNF-αmicrosatellitewith
susceptibility and progression of RA in our study population
was found to be distinct from other populations [5].
A broad array of macrophage and ﬁbroblast cytokines,
including IL-1, IL-6, IL-15, IL-18, tumor necrosis factor
(TNF-α), granulocyte-macrophage colony-stimulating fac-
tor(GM-CSF),variouschemokines,andmanyothers,ispro-
ducedbyrheumatoidsynovium.Increasedhyperplasiaofthe
synovial membrane imposed by these proinﬂammatory cy-
tokines has been suggested to play a crucial role in disease
progression [6]. In rheumatoid arthritis, joint pathology has
beenshowntobeassociatedwithhighIL1-β andTNF-αpro-
duction and TNF antagonists have proven to be the most ef-
ﬁcient therapy for RA thus far [6, 7].
TNF-α, a potent proinﬂammatory cytokine, is known to
regulate cell survival, death, and/or growth depending upon
the cell types [7]. The cytotoxic pathway involves interac-
tion of death domain-containing adapter molecules and cas-
pases leading to apoptosis, whereas the cell-protective path-
way involves activation of transcription factors, including
NF-kB [8]. TNF-α transduces its signals by binding with
TNF receptors, TNFR-I and TNFR-II (Figure 1). These two
receptors diﬀer from each other, only by the presence of a2 Mediators of Inﬂammation
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Figure 1: An overview of the TNF-α signaling pathway leading to
apoptosis or proliferation of the cells.
conserved motif in the cytoplasmic tail called the death do-
main [9]. TNFR-I mediates most of the biological proper-
ties of TNF-α, such as programmed cell death and activa-
tion of NF-kB. Upon activation, the death domain serves
as a docking site for the death domain-containing adaptor
proteins such as TRADD (TNFR associated death domain)
through homotypic death domain interaction [10]. The re-
cruitment of caspase-8 or -10 via the complex of TRADD
and FADD (Fas-associated death domain) leads to the ac-
tivation of a caspase cascade resulting in apoptosis [8, 9].
Once TRADD binds to the TNFR-I, it can also lead to the re-
cruitment of RIP (receptor interacting protein) and TRAF-2
(TNF receptor-associated factor 2). RIP is a death domain-
containing kinase that is crucial for NF-kB activation [9].
TNFR-II lacks the death domain but the intracellular do-
main of this receptor contains a consensus motif that allows
binding to TRAF-2 [11]. TRAF-2 activates both NF-kB and
JNK (cJun N-terminal kinase) and mediates its antiapop-
totic eﬀect [12]. Therefore, TNFR-II is involved in the an-
tiapoptotic eﬀect of TNF-α, whereas TNFR-I involves both
apoptotic and antiapoptotic signaling [8]. NF-kB has been
implicated in linking inﬂammatory responses to an anti-
inﬂammatorypathway[13].NF-kBisaubiquitoustranscrip-
tion factor that can be activated by proinﬂammatory agents,
such as TNF-α,I L - 1 β, LPS, oxidative stress [14]. In quies-
cent cells, NF-kB is sequestered in the cytoplasm by a set of
inhibitory molecules including I-kB. Upon stimulation by
any proinﬂammatory molecule the I-kB undergoes signal-
inducedphosphorylation andsubsequentdegradation. Once
I-kB undergoes degradation, NF-kB translocates inside the
nucleus and regulates the transcription of various inﬂamma-
tion regulatory molecules [9].
In aged humans, the role of TNF-α induced apoptosis in
decrease of T cells was examined by the expression of recep-
tors for TNF-α by peripheral blood lymphocytes [15]. In-
creased constitutive expression of TNFR-I and TRADD and
decreased expression of TNFR-II and TRAF-2 were observed
in lymphocytes from aged as compared with young controls.
These data suggest that increased TNF-α induced apoptosis
plays a role in T-cell deﬁciency associated with human aging.
TNF-α was reported to be present at high concentrations
inthebloodandsynovialﬂuidofRApatients.Therefore,dif-
ferential expression and selective usage of TNF receptors may
also workas a switch forTNF-α mediated signaling pathways
on peripheral blood mononuclear cells (PBMCs) of RA pa-
tients. An increased expression of TNFR-II as compared to
TNFR-I was also observed in synoviocytes as compared to
peripheral blood mononuclear cells [9].
This study was designed to investigate the downstream
signaling pathways of TNF-α in the PBMCs of RA pa-
tients. Expression of TNF receptors (TNFR-I and TNFR-II),
TRADD, FADD, RIP, and TRAF-2 were analyzed to under-
stand the mechanisms controlling apoptosis and prolifera-
tion in PBMCs of RA patients.
MATERIALS AND METHODS
Patientsandcontrols
Blood samples from 27 patients diagnosed with rheumatoid
arthritis were collected at the Out-Patient Department of
Rheumatology, Army Hospital, Research and Referral, New
Delhi,India,afterathoroughinvestigationbytherheumatol-
ogist. All patients fulﬁlled the American College of Rheuma-
tologyclassiﬁcationcriteriaforthedisease.Thepatientswere
diagnosed under the supervision of the rheumatologists us-
ing their medical records stating the disease duration, dura-
tion of morning stiﬀness, presence of extra-articular man-
ifestations, presence of bone deformities, rheumatoid fac-
tor, and acute phase response (erythrocyte sedimentation
rate (ESR) and C-reactive protein (CRP)). The disease ac-
tivity score using DAS-28 [16] disease score calculator was
calculated on the basis of the number of tender joints in-
volved, number of swollen joints, ESR, and visual analogue
score (VAS) for general health as subjectively estimated by
the patients. The patients had an active form of the disease
but none of them were put on any disease modifying an-
tirheumatic drugs (DMARDs). Informed consent was ob-
tained from each patient and normal individual. Both the
control and case individuals were age, sex, and ethnicity
matched. Age in the control group was 40 ± 5y e a r sa n df o r
the RA patients was 45 ± 6 years. There were 15 females and
12 males in our cohort of RA patients. The procedures fol-
lowed were in accord with the ethical standards established
by the ethics committee of the Institute and the Army Hos-
pital. Samples from 30 healthy individuals served as con-
trols.
The blood samples were collected in the sterile vacu-
tainers with ACD-A buﬀer (Greiner Bio-One GmbH). Pe-
ripheral blood mononuclear cells (PBMCs) were immedi-
atelyisolatedfromthebloodsamplesusingHistopaque-1077
(Sigma Chemicals, USA) by vendor recommended protocol.
The PBMC samples were stored at −80◦C without any freeze
thawing till the samples were further processed for RNA iso-
lation.Sunil Kumar Raghav et al 3
Table 1: Primer sequences speciﬁc for the TNF-α and TNF-α mediated signaling genes used for the ampliﬁcation of cDNA prepared from
the PBMCs of 27 RA patients and 30 healthy controls.
Gene Primer sequence Amplicon length (bp) Annealing temperature (◦C)
TNF-α 5  CAGAGGGAAGAGTTCCCCAG 3 
325 60
5  CCTTGGTCTGGTAGGAGACG 3 
TNFR-I 5  ACCAAGTGCCACAAAGGAAC 3 
263 55
5  CTGCAATTGAAGCACTGGAA 3 
TNFR-II 5  GTT GGA CTG ATT GTG GGT GTG A 3 
454 60
5  AGG GGC TGG AAT CTG TGT CTC 3 
TRADD 5  GGTTCCTTCTGCGGCTATTGCTGA 3 
251 60
5  TGAAACTGTAAGGGCTGGCTGTAA 3 
FADD 5  CTGCCTTGGCAATTCTGTTATCAG 3 
267 60
5  TGGCTGGGGTGGGGGTGGGGAGAC 3 
RIP 5  TGGGAAAGCACTGGAAAAC 3 
200 55
5  GTCGATCCTGGAACACTGGT 3 
TRAF-2 5  ACCAGCCCAGTCCTCAGATTTCAGA 3 
346 60
5  CTAGGAATGCTCCCTTCTCTCTCCAG 3 
First-strandcDNAsynthesisandgenespeciﬁc
polymerasechainreaction(PCR)
Total RNA was isolated from frozen PBMC samples by
EZ-RNA isolation kit (Biological Industries) using vendor
recommended protocol. The isolated RNA was dissolved
in DEPC (diethyl pyrocarbonate, Sigma Chemicals, USA)
treated deionized water and quantiﬁed. Two micrograms of
the total RNA were used to initiate the ﬁrst-strand cDNA
synthesis using Advantage RT-for-PCR Kit (BD Clontech) by
following vendor’s recommended procedure. Control RNA
and the primers for G3PDH are included in the kit and were
used to validate the quality of cDNA synthesized for each re-
action.GenespeciﬁcprimersweredesignedusingtheDNAS-
TAR software. Primer sequences speciﬁc for the TNF-α me-
diated signaling genes are presented in Table 1. The ﬁrst-
strand cDNA was diluted 1 : 5 with the deionized water
and used for gene speciﬁc PCR reactions. The TNF-α me-
diated signaling genes were ampliﬁed with a DNA thermal
cycler (MJ Research, Perkin Elmer) using the diluted cDNA,
25mM MgCl2, 1.25mM dNTP, 10pM each of the forward
and reverse primer and 2.5U of Taq DNA polymerase. After
an initial denaturation at 94◦C for 4min, the ampliﬁcation
w a sc o n d u c t e df o r3 5c y c l e sa t9 4 ◦C for 30s, primer speciﬁc
annealing temperature (Table 1) for 30s, 72◦Cf o r6 0sa n da
ﬁnalextensionfor7minat72◦C.ThePCRproductwasvisu-
alized on a 1.2% agarose gel. The density of each band (PCR
product) was measured using Image Scan and Analysis Sys-
tem (Alpha Innotech Corporation, USA) with Digidoc 1201
software.
Statisticalanalysis
All data presented represent the mean and standard error
(SE) for n determinations. Data analyses were performed us-
ing the World Wide Web available software. The density of
PCR product for each sample was measured and the relative
density mean (the value of the intensity of PCR product di-
vided by the intensity for G3PDH) was calculated. All pair-
wise multiple comparisons were made using the Student t-
test. The two tailed P values equal to or less than 0.05 were
considered signiﬁcant. Means ± SD (standard deviation) of
the raw data used for normalization is presented in the re-
sults.
RESULTS
ExpressionofgenesinvolvedintheTNF-α
mediatedsignalingpathway
We analyzed the constitutive expression of the genes that are
involved in TNF-α mediated signaling in PBMCs of 30 nor-
mal healthy controls and 27 RA patients. We observed the
following signiﬁcant diﬀerences in the gene expression pro-
ﬁle of the RA patients in comparison to the healthy controls.
ExpressionofTNF-α,TNFR-I,andTNFR-IIgenes
PBMCs from RA patients revealed a stronger expression of
TNF-α and TNFR-I mRNA than those from the controls
(Figure 2).Therewasastatisticallysigniﬁcantdiﬀerence(P<
0)betweentheexpressionofTNF-αintheRApatients(mean
± SD = 1.607 ± 0.39) with the healthy controls (mean ± SD
= 1.0215 ± 0.224). An increase (P<. 0003) in the expres-
sion of TNFR-I was observed in the RA patients (mean ±
SD = 2.1289 ± 0.8117) as compared to the healthy controls
(1.398 ±0.5428, mean ± SD, Figure 2). However, we did not
ﬁnd an altered expression of TNFR-II gene in the PBMCs of
thecontrols/casesinourcohort.Thelevelofthegeneexpres-
sion in the controls (mean ± SD = 1 ± 0) was similar to that
intheRApatients(mean ±SD=1±0)withoutanystatistical
signiﬁcance (P = .692).4 Mediators of Inﬂammation
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Figure 2: (a) Agarose gel (1.2%) showing gene expression proﬁle of
TNF-α, TNFR-I, and TNFR-II from PBMCs of ﬁve representative
healthy controls and RA patients. G3PDH gene was used for esti-
mating the relative density of gene speciﬁc expression. (b) Relative
density mean (density of gene speciﬁc product/density of house-
keeping gene G3PDH) of 30 healthy controls and 27 RA patients
for the expression of the genes.
ExpressionofTRADDandFADDgenes
The representative RT-PCR gels demonstrating the expres-
sion of TRADD and FADD genes from control and RA cases
areshowninFigure 3.Asevident,therewasastatisticallysig-
niﬁcant increase in the expression of TRADD gene (P<0) in
the RA patients (mean ± SD = 1.919±0.581) in comparison
tothenormalhealthycontrols(mean ±SD=1.312±0.2885).
However, the FADD gene was observed to be equally ex-
pressed in both the cases and the controls (patients mean ±
SD = 1.497 ±0.782, controls mean ± SD = 1.7816 ±0.360).
ExpressionofRIPandTRAF-2genes
On analyzing the expression of RIP and TRAF-2 genes in the
controls and RA patients (Figure 4), we observed an increase
in the expression of both the RIP (P = 0.0123) and TRAF-2
genes (P = 0) in RA patients (RIP: mean ± SD = 2.9799 ±
1.4946, TRAF2: mean ± SD = 1.942 ± 0.564) as compared
to the healthy controls (RIP: mean ± SD = 2.0966 ± 0.9343,
TRAF2: mean ± SD = 1.1944 ±0.582).
DISCUSSION
Rheumatoid arthritis (RA), an autoimmune disease, is char-
acterized by chronic inﬂammatory symptoms leading to
damage of synovial tissue and joints. Proinﬂammatory cy-
tokines like TNF-α reportedly contributes to the pathogene-
sis of rheumatoid arthritis [17]. In support of such reports
we also observed an overexpression of TNF-α gene in the
PBMCs of RA patients as compared to the healthy controls.
TNF-α is associated with various cell signaling systems via
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Figure 3: (a) Gene expression proﬁle of TRADD and FADD from
PBMCs of representative healthy controls and RA patients. (b)
Relative density mean (density of gene speciﬁc product/density of
housekeeping gene G3PDH) of 30 healthy controls and 27 RA pa-
tients for the expression of TRADD and FADD genes.
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Figure 4: (a) Agarose gel (1.2%) showing gene expression proﬁle
of RIP and TRAF-2 from PBMCs of ﬁve representative healthy con-
trols and RA patients. (b) Graph showing the relative density mean
of 30 healthy controls and 27 RA patients for the expression of RIP
and TRAF-2 genes.
two types of cell surface receptors, TNFR-I (p55) and TNFR-
II (p75) [8, 10]. TNFR-I is involved in both proapoptotic
andantiapoptoticsignalingviatheinteractionwithTRADD-
FADD and TRADD-RIP-TRAF-2, respectively, [10]. Both
TNFR-I and Fas-mediated apoptotic pathways use FADD as
a common conduit [18] for the activation of apoptotic sig-
naling. In contrast, TNFR-II is involved in an antiapoptotic
eﬀect of TNF-α via TRAF-2 [8].Sunil Kumar Raghav et al 5
The present study, for the ﬁrst time, demonstrates that
the PBMCs of RA patients showed an overexpression of
TNFR-I and TRADD genes in comparison to the healthy
controls; however, only a mild increase in TNFR-II expres-
sion was observed. Overexpression of TRADD results in
apoptoticcelldeathviaTNF-αinducedactivationofcaspases
as reported in many cell lines [19]. We observed a similar
expression of the FADD gene among the RA patients and
the healthy controls. This result indicates that the TNF-α-
TRADD/FADD induced apoptotic pathway is not being fol-
lowed in the PBMCs of the RA patients.
We observed a constitutive expression of TNFR-II gene
in both the controls and the RA patients without any statisti-
cal signiﬁcance. This nulliﬁes any signiﬁcant overexpression
oftheTNFR-IImediatedproliferative/antiapoptoticpathway
intheRApatients.HowevertheTRAF-2andRIPgenesinthe
PBMCs were signiﬁcantly over expressed among the RA pa-
tients. This demonstrates a signiﬁcant overexpression of the
antiapoptotic pathway in the PBMCs of the RA patients in
contrast to the healthy individuals.
Our observations of increased TRAF-2/RIP expression in
PBMCs suggest that an increased TRAF-2/RIP may result in
TNF-α induced proliferation via NF-kB-dependent pathway.
In conclusion, PBMCs of the RA patients are observed
to be more susceptible to TNF-α induced proliferation as
compared to control subjects and are associated with a de-
creased expression of molecules (FADD) involved in apop-
totic pathways. Increased expression of TNF-α in the PBMCs
and increased susceptibility of these cells to TNF-α induced
antiapoptosis may play a role in the pathogenesis of the dis-
ease.
The present study therefore supports the notion that the
changes in the expression of TNF-α associated downstream
moleculesaremorecomplicatedthantheexpressionofTNF-
α/TNFreceptors.Thisisprobablycausedbythecomplexreg-
ulatory mechanisms including cross talks with other signal-
ing pathways that function in association with TNF-α medi-
ated signaling pathways.
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